Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.61)
# 3,879
Out of 4,883 analysts
55
Total ratings
28.57%
Success rate
-30.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $4.14 | +166.02% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $13.19 | +135.03% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.51 | +1,157.86% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $3.80 | +452.63% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $2.58 | +93.80% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.29 | +1,140.31% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $0.23 | +4,244.05% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $9.75 | +156.41% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $0.87 | +22,888.53% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.03 | +579.61% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.12 | +792.86% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $7.25 | +727.57% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.32 | +1,763.93% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.01 | +149.38% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.72 | +33,141.00% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $6.90 | +2,537.68% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.20 | +40,820.72% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.23 | +796.86% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.44 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.02 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.56 | +284.62% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.40 | +183.78% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $8.55 | +122,707.02% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.31 | +1,499.52% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $24.55 | +1,122.00% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $541.95 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $68.71 | +29.54% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $129.50 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.90 | +111,011.11% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.05 | +16,330.32% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.27 | +450.46% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $4.14
Upside: +166.02%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $13.19
Upside: +135.03%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.51
Upside: +1,157.86%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $3.80
Upside: +452.63%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $2.58
Upside: +93.80%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.29
Upside: +1,140.31%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $0.23
Upside: +4,244.05%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $9.75
Upside: +156.41%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $0.87
Upside: +22,888.53%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.03
Upside: +579.61%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.12
Upside: +792.86%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $7.25
Upside: +727.57%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.32
Upside: +1,763.93%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.01
Upside: +149.38%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.72
Upside: +33,141.00%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $6.90
Upside: +2,537.68%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.20
Upside: +40,820.72%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.23
Upside: +796.86%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.44
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.02
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.56
Upside: +284.62%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $7.40
Upside: +183.78%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $8.55
Upside: +122,707.02%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.31
Upside: +1,499.52%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $24.55
Upside: +1,122.00%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $541.95
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $68.71
Upside: +29.54%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $129.50
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.90
Upside: +111,011.11%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.05
Upside: +16,330.32%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.27
Upside: +450.46%